Pharma Mar, S.A.: Business Overview, Financials & Competitive Analysis

Pharma Mar, S.A. Overview

Pharma Mar is a global leader in the research, development, and commercialization of marine-derived oncology therapies. The company discovers new anti-tumour molecules of marine origin and markets key products including Yondelis (trabectedin) for soft tissue sarcoma and ovarian cancer, Aplidin (plitidepsin) for multiple myeloma, and Zepzelca (lurbinectedin) for small cell lung cancer. The company allocates 61.3% of its revenues to R&D, nearly three times higher than the next Spanish company and consolidates over a decade of leadership in this classification.

Strategic Profile

Pharma Mar operates through Oncology and RNA Interference segments and was incorporated in 1986, based in Madrid, Spain. The company has achieved a 37.5% success rate in its investigations, far exceeding the 10.8% industry average, with eight compounds reaching clinical trials and three approved. The company operates through subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the US.

Competitive Landscape

The company targets the global oncology market with focus on the world's main oncology markets. Pharma Mar competes with large-cap pharma players like Eli Lilly, Merck, and Bristol Myers Squibb in oncology, as well as smaller biotech firms specializing in rare cancers and RNA interference therapeutics. The marine-derived platform and exceptional clinical success rate provide differentiation, though scale and commercialization capabilities lag major competitors.

Industry Context

Pharma Mar, S.A. operates in Biopharmaceuticals & Oncology.

Key facts

Founded: 1986 · Headquarters: Madrid, Spain · Employees: 500 · Revenue: $189.2M · Market cap: $1.7B